# Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease

> **NCT00102115** · PHASE1 · TERMINATED · sponsor: **Light Sciences LLC** · enrollment: 27 (—)

## Conditions studied

- Macular Degeneration
- Choroidal Neovascularization

## Interventions

- **DRUG:** Talaporfin Sodium (LS11) Photodynamic Therapy (PDT)

## Key facts

- **NCT ID:** NCT00102115
- **Lead sponsor:** Light Sciences LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-12
- **Primary completion:** —
- **Final completion:** 2006-01
- **Target enrollment:** 27 (—)
- **Last updated:** 2010-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00102115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00102115, "Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00102115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*